Millions of people are victims of rare diseases across the globe. The opportunities and threats that each condition present to a small patient group will add up to a significant societal health issue. To drug developers, the science is complicated, recruiting patients is laborious, and it is costly. To fill this loophole, the US FDA established the orphan drug designation program. In case you...